ArticleCell reports. Medicine2020
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.
Article in Cell reports. Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02817997 (ACCELERATE), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Breast-implant associated unicentric castleman disease: a case report.Current problems in cancer. Case reports · 2026Article
- Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.Frontiers in oncology · 2026Article
- Oligocentric Castleman Disease (OligoCD): A Novel Diagnostic Entity in the Spectrum of Castleman Disease.Cureus · 2025Article
- Expanding research and care for Leigh syndrome: efforts of a patient-led advocacy organization.Research involvement and engagement · 2025Article
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry.Blood advances · 2025Article
- No evidence for active viral infection in unicentric and idiopathic multicentric Castleman disease by Viral-Track analysis.Scientific reports · 2025Article
- Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients.Frontiers in immunology · 2025Article
- Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis.European journal of haematology · 2024Article
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.Haematologica · 2024Article
- Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination.Blood neoplasia · 2024Article
- Do people with ME/CFS and joint hypermobility represent a disease subgroup? An analysis using registry data.Frontiers in neurology · 2024Article
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.Blood advances · 2023Article
- Leigh syndrome global patient registry: uniting patients and researchers worldwide.Orphanet journal of rare diseases · 2023Article
- A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases.Orphanet journal of rare diseases · 2023Article
- CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.Nature communications · 2022Article
- Article
- How we manage idiopathic multicentric Castleman disease.Clinical advances in hematology & oncology : H&O · 2022Article
- The Facilitation of Clinical and Therapeutic Discoveries in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Related Diseases: Protocol for the You + ME Registry Research Platform.JMIR research protocols · 2022Article
- The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.British journal of haematology · 2022Article
- International definition of iMCD-TAFRO: future perspectives.Journal of clinical and experimental hematopathology : JCEH · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 16 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Geographically dispersed patients, inconsistent treatment tracking, and limited infrastructure slow research for many orphan diseases. We assess the feasibility of a patient-powered study design to overcome these challenges for Castleman disease, a rare hematologic disorder. Here, we report initial results from the ACCELERATE natural history registry. ACCELERATE includes a traditional physician-reported arm and a patient-powered arm, which enables patients to directly contribute medical data and biospecimens. This study design enables successful enrollment, with the 5-year minimum enrollment goal being met in 2 years. A median of 683 clinical, laboratory, and imaging data elements are captured per patient in the patient-powered arm compared with 37 in the physician-reported arm. These data reveal subgrouping characteristics, identify off-label treatments, support treatment guidelines, and are used in 17 clinical and translational studies. This feasibility study demonstrates that the direct-to-patient design is effective for collecting natural history data and biospecimens, tracking therapies, and providing critical research infrastructure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.